RWLK REWALK ROBOTICS LTD

DEADLINE ALERT: Brower Piven Reminds Investors of the March 27, 2017 Deadline in Class Action Lawsuit and Encourages Investors with Losses in Excess of $100,000 from Investment in ReWalk Robotics Ltd. to Contact the Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of ReWalk Robotics Ltd. (Nasdaq: RWLK) (ReWalk or the “Company”) common stock issued in connection with ReWalk's initial public offering conducted on or about September 12, 2014 (the “IPO”). Investors who wish to become proactively involved in the litigation have until March 27, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in ReWalk’s IPO on or about September 12, 2014. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Act of 1933 by virtue of the defendants’ failure to disclose in connection with the Company’s initial public offering that ReWalk was unprepared and/or unable to comply with applicable “special controls” requirements or to provide the U.S. Food and Drug Administration (“FDA”) with a post-market surveillance study as required for the Company to maintain ongoing sales of its products.

According to the complaint, following a September 30, 2015 warning letter from the FDA outlining the failure to detail an adequate post-market surveillance plan, which was disclosed to the public by the FDA on February 25, 2016, the value of ReWalk shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in ReWalk’s September 12, 2014 IPO and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
21/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Ltd. Reports Second Quarter 2025 Financial Results

Lifeward Ltd. Reports Second Quarter 2025 Financial Results Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations o...

 PRESS RELEASE

Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadersh...

Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously served as the Company’s Vice President of Finance and Chief Accounting Officer, has been appointed as the Company’s new Chief Financial Officer. "I am thrilled to welcome Almog to the executive leadership t...

 PRESS RELEASE

Lifeward to Report Second Quarter Financial Results on August 14, 2025

Lifeward to Report Second Quarter Financial Results on August 14, 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Vice President of Finance, will host a conferen...

 PRESS RELEASE

Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add C...

Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region Expansion adds additional AlterG dealer coverage to 6 countries throughout the Gulf Cooperation Council region MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the expansion of its relationship with SportsMed Produ...

 PRESS RELEASE

Lifeward Announces Closing of $2.6 Million Public Offering

Lifeward Announces Closing of $2.6 Million Public Offering MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch